Advertisement

Pharmaceutical Chemistry Journal

, Volume 46, Issue 2, pp 96–102 | Cite as

Synthesis and pharmacological activity of analogs of the endogenous neuropeptide cycloprolylglycine

  • K. N. Kolyasnikova
  • M. V. Vichuzhanin
  • M. A. Konstantinopol’skii
  • S. S. Trofimov
  • T. A. Gudasheva
Article
First Online:
Received:

A series of analogs and homologs of the endogenous cyclic dipeptide cycloprolylglycine were synthesized. The nootropic properties of the synthesized compounds were investigated on an experimental model of a passive avoidance test with electroshock- or scopolamine-induced amnesia. The anxiolytic activity was examined by an elevated plus-maze test. It is established that the pharmacophores responsible for the nootropic and anxiolytic activities are different. Hypotheses concerning the structure of the binding regions with the corresponding pharmacological targets are formulated.

Key words

cyclic dipeptides cycloprolylglycine nootropic activity anxiolytic activity 
This is a preview of subscription content, log in to check access.

References

  1. 1.
    T. A. Gudasheva, R. U. Ostrovskaya, F. V. Maksimova, et al., Khim.-farm. Zh., 23(3), 276 – 281 (1989).Google Scholar
  2. 2.
    T. A. Gudasheva, S. S. Boyko, V. Kh. Akparov, et al., FEBS Lett., 391, 149 – 152 (1996).PubMedCrossRefGoogle Scholar
  3. 3.
    T. A. Gudasheva, R. U. Ostrovskaya, S. S. Trofimov, et al., Byull. Eksp. Biol. Med., 116(10), 411 – 413 (1999).Google Scholar
  4. 4.
    T. A. Gudasheva, M. A. Konstantinopol’skii, R. U. Ostrovskaya, et al., Byull. Eksp. Biol. Med., 131(5), 547 – 550 (2001).CrossRefGoogle Scholar
  5. 5.
    T. A. Gudasheva, N. I. Vasilevich, R. U. Ostrovskaya, et al., Khim.-farm. Zh., 30(9), 12 – 17 (1996).Google Scholar
  6. 6.
    L. S. Nazarova, Yu. B. Rozanov, A. M. Likhosherstov, et al., Khim.-farm. Zh., 18(12), 1445 – 1448 (1984).Google Scholar
  7. 7.
    H. D. Dakin, J. Biol. Chem., 44, 499 – 529 (1920).Google Scholar
  8. 8.
    H. Suli-Vargha, J. Bodi, M. Meszaros, et al., J. Med. Chem., 31(8), 1492 – 1495 (1988).PubMedCrossRefGoogle Scholar
  9. 9.
    B. R. de Costa, X. He, J. T. M. Linders, et al., J. Med. Chem., 36(21), 2311 – 2320 (1993).PubMedCrossRefGoogle Scholar
  10. 10.
    E. L. Smith and M. Bergmann, J. Biol. Chem., 153, 627 – 651 (1944).Google Scholar
  11. 11.
    I. L. Rodionov, L. N. Rodionova, L. K. Baidakova, et al., Tetrahedron, 58, 8515 – 8523 (2002).CrossRefGoogle Scholar
  12. 12.
    T. Kanemitsu, Y. Ogihara, and T. Takeda, Chem. Pharm. Bull., 45(4), 643 – 650 (1997).CrossRefGoogle Scholar
  13. 13.
    R. Ader, J. A. W. M. Weinen, and P. Moleman, Psychon. Sci., 26(3), 125 – 128 (1972).Google Scholar
  14. 14.
    T. A. Voronina, Sov. Med. Rev. G. Neoropharmacology, 2, 51 – 106 (1992).Google Scholar
  15. 15.
    S. Pellow, P. Chopin, S. E. File, et al., J. Neurosci. Methods, 14, 149 – 167 (1985).PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, Inc. 2012

Authors and Affiliations

  • K. N. Kolyasnikova
    • 1
  • M. V. Vichuzhanin
    • 1
  • M. A. Konstantinopol’skii
    • 1
  • S. S. Trofimov
    • 1
  • T. A. Gudasheva
    • 1
  1. 1.MoscowRussia

Personalised recommendations

Cite article

Buy options